About Anaplastic Thyroid Cancer
Anaplastic thyroid cancer is a type of thyroid cancer. It least common (only 1% of all thyroid cancer cases) and most deadly of all thyroid cancers. It is more common in older people with an average age of about 60 and it is more common in women than in men. The cause of anaplastic thyroid cancer is not known. It is very rare in young patients. Anaplastic thyroid cancer is usually too aggressive and invasive when it is diagnosed. It can be diagnosed with the help of biopsy and imaging tests. The treatment of anaplastic thyroid cancer includes surgery, radiation therapy and chemotherapy.
Attributes | Details |
---|
Study Period | 2018-2030 |
Base Year | 2023 |
Unit | Value (USD Million) |
The market is concentrated by a few players. Once the above molecules get approved, it will intensify the competition in the Thyroid Cancer Market which will result in substantial growth in the market. The competition in the market appears to be less. Some effective treatments like Surgery exist and chemotherapy drugs are in practice. Companies such as Doxorubicin aim at managing conditions and are prone to achieve larger success in the future. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Anaplastic Thyroid Cancer market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.
GlaxoSmithKline plc. (United Kingdom), OXiGENE, Inc. (United States), Daiichi Sankyo Company Limited (Japan), Immune Pharmaceuticals, Inc. (United States), Exelixis, Inc. (United States), Bristol-Myers Squibb Co. (United States), Celgene Corp. (United States), Eisai Co. Ltd. (Japan), Johnson & Johnson Services Inc. (United States) and Novartis AG (Switzerland) are some of the key players that are part of study coverage.
Segmentation Overview
AMA Research has segmented the market of Global Anaplastic Thyroid Cancer market by , Application (Hospitals, Clinics and Ambulatory Surgery Centers) and Region.
On the basis of geography, the market of Anaplastic Thyroid Cancer has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Surgery will boost the Anaplastic Thyroid Cancer market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis, the sub-segment i.e. Imaging (Ultrasound, CT and MRI) will boost the Anaplastic Thyroid Cancer market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Influencing Trend:
High Demand for Advanced Treatment for Anaplastic Thyroid Cancer
Market Growth Drivers:
High Prevalence of Thyroid Cancer, Rising Awareness among the People about Cancer and Its Treatment and Increase in Healthcare Expenditure
Challenges:
Stringent Rules and Regulations of the Government
Restraints:
Adverse Effects of the Chemotherapy
Opportunities:
Growing Geriatric Population Worldwide and Development of Healthcare Infrastructure in Emerging Economics
Market Leaders and their expansionary development strategies
On September 14, 2023, Merck and Incyte entered into a strategic partnership to develop and commercialize a novel oral tyrosine kinase inhibitor (TKI) for the treatment of advanced thyroid cancers, including Anaplastic Thyroid Cancer.
On August 10, 2023, Eli Lilly and Company announced the launch of Verzenio (abemaciclib) in India for the treatment of locally advanced or metastatic breast cancer, which can be used in combination with other therapies for some patients with Anaplastic Thyroid Cancer.
Key Target Audience
Anaplastic Thyroid Cancer Treatment Providers, Research Institutes, Emerging Companies, Government Body & Associations and End-user
About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.